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Matrilysin-2 (matrix metalloproteinase (MMP)-26) is a small protein of the MMP family expressed in some epithelial
carcinomas and normal tissues. We studied its role in benign skin disorders characterized by epithelial prolif-
eration, in wound repair, skin cancer, and regulation in keratinocyte (KC) cultures. MMP-26 is expressed by laminin-
5-positive KC in the migrating area during wound repair, in benign skin disorders characterized by inﬂammation
and microdisruptions of basement membrane, but in intact skin only in hair follicles. It was detected in occasional
atypical KC in pre-malignant lesions but not in basal cell cancer islands. Although MMP-26 was expressed in
grades I and II squamous cell cancers (SCC), it was not present in dedifferentiated grade III tumors. MMP-26 was
neither co-expressed with its close homologue matrilysin-1 nor with the proliferation marker Ki-67. But in tissue
samples it either co-localized or was detected in adjacent cells of same regions with the tumor suppressor p16. In
KC and HaCaT cell cultures, 12-phorbol-13-myristate-acetate, epidermal growth factor, tumor necrosis factor-a,
transforming growth factor-b1, interleukin-1 (IL-1)b, IL-6, insulin-like growth factor, c-IFN, retinoic acid, dexamet-
hasone, four matrices or ras-transformation were unable to upregulate MMP-26 expression. The expression pattern
of MMP-26 suggests that it may be upregulated in basal KC even without tumorigenesis because of altered cell–
matrix interactions and inﬂammation and, unlike most MMP, becomes downregulated during histological dedif-
ferentiation of SCC. Thus, lack of MMP-26 in SCC could be a marker of aggressive growth.
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Matrix metalloproteinases (MMP) degrade all components
of the extracellular matrix and basement membranes (BM),
events essential in cell motility, angiogenesis, and cancer
metastasis. Identification of many non-matrix substrates
and new bioactivities of their proteolytic cleavage products
have evidenced that MMP regulate additional cellular func-
tions during tumor development, such as cell proliferation,
differentiation, and apoptosis (Egeblad and Werb, 2002;
Overall and Lope´z-Otı´n, 2002). Under normal physiologic
conditions most MMP are expressed at very low levels in
adult human skin, but become upregulated during, e.g.,
blistering, wound repair, inflammation, carcinogenesis, and
photoaging (see Egeblad and Werb, 2002; Kerkela¨ and
Saarialho-Kere, 2003).
MMP-26 (also known as endometase and matrilysin-2),
the smallest MMP currently known, was isolated from hu-
man fetal pool, placental, and endometrial tumor cDNA by
three groups (de Coignac et al, 2000; Park et al, 2000; Urı´a
and Lope´z-Otı´n, 2000). It is 261 amino acids long and con-
tains the signal sequence for secretion, prodomain with an
unclassical cysteine-switch for preservation of latency and
the catalytic domain with the Zn2þ -ion in the catalytic cen-
ter for activity. MMP-26 can undergo autocatalytic activa-
tion, a feature exceptional among MMP (Marchenko et al,
2002b). The gene for MMP-26 is located in the short arm of
chromosome 11, a site distinct from the cluster of many
classical MMP (Urı´a and Lope´z-Otı´n, 2000).
MMP-26 degrades in vitro type IV collagen, fibronectin,
fibrinogen, vitronectin, denaturated collagen types I–IV, a1-
antitrypsin, a2-macroglobulin (Urı´a and Lope´z-Otı´n, 2000;
Marchenko et al, 2001), and insulin-like growth factor-bind-
ing protein 1 (IGFBP-1) (Park et al, 2002). Additionally, it
activates pro-MMP-9 (Urı´a and Lope´z-Otı´n, 2000) in a spe-
cific site to create gelatinase species that are more stably
active than when processed by, e.g., MMP-7 (Zhao et al,
2003). In contrast, tenascin C, laminin-5 (LN-5), and native
collagen types I–III are resistant to proteolysis by MMP-26
(Marchenko et al, 2001). Tissue inhibitors of metal-
loproteinases-2 and -4 can inhibit MMP-26 activity (Zhao
et al, 2004).
MMP-26 expression has been found in several cancer
cell lines in culture (Urı´a and Lope´z-Otı´n, 2000; Marchenko
Abbreviations: BM, basement membrane; BCC, basal cell cancer;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KC, kera-
tinocyte; LN-5, laminin-5; MMP, matrix metalloproteinase; SCC,
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et al, 2001). A significant level of expression in healthy tis-
sues has been found to date by northern analysis in the
uterus, kidney, and placenta, and by RT-PCR in cancers of
the endometrium, lung, prostate, and mammary gland (de
Coignac et al, 2000; Park et al, 2000; Urı´a and Lope´z-Otı´n,
2000; Marchenko et al, 2001). In vivo data on human MMP-
26 protein are limited to normal human cytotrophoblasts
(Zhang et al, 2002), normal endometrial glands (Isaka et al,
2003; Pilka et al, 2003), as well as endometrial (Tunuguntla
et al, 2003), prostate (Zhao et al, 2003), and breast cancers
(Zhao et al, 2004). Therefore, MMP-26 might be involved in
implantation, be an inflammatory mediator in some disor-
ders and a target enzyme in the treatment for cancer and
other pathological conditions.
The aim of this study was to investigate the putative ex-
pression and regulation of MMP-26 in epithelial cells and its
role in cutaneous biology. We show here that MMP-26 pro-
tein can be expressed by keratinocytes (KC) in association
with various benign skin disorders, in wound repair and
early skin carcinogenesis. Unlike observed with classical
MMP, the expression of MMP-26 becomes downregulated
in aggressive, dedifferentiated skin cancers.
Results
MMP-26 protein was detected in the migrating KC of nor-
mally healing wounds (Figs 1A and 2A). The number of
positive cells clearly increased from day 1 onwards and
MMP-26 protein was still evident in the basal KC of open
9 d wounds. It co-localized with cytoplasmic LN-5, a marker
for KC migration (Fig 1B). Since MMP-26 was recently pos-
tulated to be an activator of MMP-9 at least in cancer (Zhao
et al, 2003), we stained consecutive sections of normally
healing wounds for MMP-9, but found no significant co-
localization (Fig 1C). The epithelial tip bordering chronic ul-
cers of various etiologies was generally also positive for
MMP-26 (Fig 1D). Fibroblasts, endothelial cells, and ne-
utrophils were always negative. No staining for MMP-26
was detected in the epidermis of normal intact skin (Fig 1H)
or developing skin from week 20 (data not shown). But it
was present in the outer root sheath of anagen hair follicles
(Fig 1H), but not markedly expressed in the telogen and
catagen phases.
To investigate the possible contribution of KC prolifera-
tion to induction of MMP-26, samples of psoriasis and
keratoacanthoma were immunostained. In psoriasis hyper-
proliferative KC were negative, except for occasional basal
KC at the top of dermal papillae, where the BM zone usually
has microdisruptions (Suomela et al, 2003) (Fig 1E). Positive
KC were detected in all keratoacanthomas in the pushing
border of these tumors (data not shown). MMP-26 was also
detected in 2/3 samples of lichen planus co-inciding with
areas of heavy inflammatory infiltration in the vicinity of ba-
sal KC (putative BM disruptions) (Fig 1F), whereas chronic
eczema samples were generally negative. Specimens of
seborrhoeic keratosis had occasionally positive KC (Fig 1G),
whereas in actinic keratoses and Bowen’s disease, some
basal KC were positive, particularly those with cellular aty-
pia (Figs 3A and 2C).
MMP-26 was not detected in basal cell cancers (BCC)
islands (Fig 3B). But basal KC adjacent to BCC expressed
MMP-26 in E-cadherin-negative areas (Fig 3B,C). In BCC or
squamous cell cancers (SCC), MMP-26 expression did not
co-localize with proliferating Ki-67-positive KC (Fig 3B,D
and data not shown).
Intensive staining for MMP-26 was detected particularly
in microinvasive (Fig 4A), grades I and II SCC, in which it co-
localized with LN-5 at the invasive front (Fig 4C–F). Unlike
with classical MMP, the invasive areas of histologically ag-
gressive grade III SCC were negative (Fig 4G). MMP-9 was
often detected in the same areas as MMP-26, but adjacent
to it, and MMP-9-positive cells were clearly fewer compared
with MMP-26-positive cells (Fig 4H, I). MMP-26 did not co-
Figure 1
Matrix metalloproteinase (MMP)-26 is
expressed in keratinocyte (KC) during
wound repair. (A) Immunostaining for
MMP-26 in a normally healing 2 d wound.
(B) Immunostaining for laminin-5 in a se-
rial section. (C) Immunostaining for MMP-
9 does not co-localize with MMP-26. Also
MMP-9-positive neutrophils are seen. Ar-
rows depict positive KC and U the loca-
tion of the wound. (D) Immunostaining for
MMP-26 in a chronic wound. (E) MMP-26
is positive in KC on top of rete ridges in
psoriasis. (F) Immunostaining for MMP-26
in a sample of lichen planus. (G) Occa-
sional expression for MMP-26 protein in
seborrhoeic keratosis. (H) MMP-26 is ex-
pressed in anagen hair follicles, but not in
normal skin. Scale bars: 25 mm (A–C); 125
mm (D and H); 50 mm (E–G).
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localize with MMP-7 or nuclear b-catenin in cancer tissues
and was never detected in sweat glands like MMP-7 (data
not shown). Damaged elastin in the mid-dermis was often
positive for MMP-26 in skin cancer samples (Fig 4A,B) and
also in yet benign samples with photodamage, MMP-26-
stained elastic fibers (data not shown).
As MMP-26 seemed to be associated with early events
in tumorigenesis at tissue level, we examined its relation to
the tumor suppressor gene p16, recently shown to be in-
duced in cells of some pre-malignant lesions and consist-
ently during the early stage of SCC invasion (Natarajan et al,
2003). MMP-26 co-localized with p16 in migrating KC dur-
ing normal wound healing (Fig 2A,B). In Bowen’s disease,
p16 was much more widely expressed than MMP-26, which
was detected only basally. In microinvasive and grade I
SCC, MMP-26 and p16 partly co-localized (Fig 2E,F), but in
grade II SCC they were expressed in the same regions, but
by adjacent cells (Fig 2G,H).
In accordance with our tissue data, MMP-26 protein was
demonstrable also in cultured primary KC, HaCaT, and
A-431 cells (Fig 5).
We cultured HaCaT cells and primary KC on plastic in the
presence of various cytokines and growth factors. 293 cells,
human placenta, and testis were used as positive controls
in the RT-PCR and TaqMan (Applied Biosystems, Warring-
ton, UK) analyses (Fig 6 and data not shown). The basal
levels for MMP-26 mRNA expression in primary KC and
HaCaT cells, when assessed by TaqMan analysis and con-
ventional RT-PCR, were low when compared with our pos-
itive controls (Fig 6). With the concentrations and time
points used, none of the agents administered seemed to
consistently influence MMP-26 mRNA levels, as assessed
by TaqMan real-time quantitative PCR (Fig 6). Furthermore,
we cultured HaCaT cells and primary KC on various matri-
ces, but saw no significant upregulation of MMP-26 mRNA
with collagen I, collagen IV, LN-1, or fibronectin either.
MMP-26 expression was not upregulated by ras-transfor-
mation of HaCaT, as MMP-26 mRNA levels did not increase
with malignant potential of the various HaCaT clones (Ha-
CaT, immortalized; A5, tumorigenic; II-4, invasive; RT3,
metastatic) as assessed by TaqMan real-time quantitative
PCR, conventional PCR, and immunostaining of HaCaT
clones cultured on chamber slides (data not shown).
Discussion
In this study, we show for the first time that MMP-26 is
produced in vivo by migrating KC in response to skin injury,
like several other MMP (see Saarialho-Kere et al, 2002), but
not in normal intact epidermis. This is in accordance with
recent data from our group, demonstrating MMP-26 in mi-
grating enterocytes bordering intestinal wounds (Bister et al,
2004). Our positive results in chronic wounds (Fig 1) agree
with previous data on MMP-1 and -10, which are also ex-
pressed in KC bordering both normally healing and non-
healing wounds (Vaalamo et al, 1996). MMP-26 is known to
shed IGFBP-1 at least in vitro (Park et al, 2000). Proteolysis
of IGFBP-1 represents a mechanism to increase IGF bio-
availability, which in turn stimulates re-epithelialization (Vogt
Figure 2
Matrix metalloproteinase (MMP)-26 and p16 co-localize in wounds
but not in dedifferentiated cancers. (A) Staining for MMP-26. (B) p16
in an acute wound. (C) Staining for MMP-26. (D) p16 in Bowen’s dis-
ease. (E) Staining for MMP-26. (F) p16 in a microinvasive squamous cell
cancer (SCC). (G) Staining for MMP-26. (H) p16 in serial sections of a
grade II SCC. Arrows depict corresponding spots. Scale bars: 25 mm
(A, B); 50 mm (C–F); 125 mm (G, H).
Figure3
Matrix metalloproteinase (MMP)-26 is expressed in actinic kera-
tosis, but does not co-localize with the proliferation marker Ki-67.
(A) MMP-26 is expressed in keratinocytes with atypia in actinic kera-
tosis. (B) Immunostaining for MMP-26 in a basal cell cancer. (C) Serial
section stained with E-cadherin. (D) The proliferation marker Ki-67. Ar-
rows depict corresponding spots. Scale bars: 50 mm (A); 25 mm (B–D).
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et al, 1998). Although this study was in progress, MMP-26
was suggested to be a wnt target gene (Marchenko et al,
2004). Genes of the wnt pathway are known to regulate
morphology, cell cycle, pericellular proteolysis, and cell lo-
comotion.
MMP-26 protein was also detected in basal KC in those
areas of lichen planus, where a large dermal infiltration of
inflammatory cells was observed beneath the epidermis.
The same phenomenon was seen in keratoacanthomas,
which are usually characterized by prominent inflammation.
In another inflammatory skin disorder, psoriasis, MMP-26
was upregulated in basal KC at the tip of dermal papillae. It
is possible that in benign skin disorders basal MMP-26 ex-
pression relates to altered cell–matrix interactions via mi-
crodisruptions of the BM or to altered cytokine milieu.
MMP-26 is not associated with mere KC proliferation as our
results in psoriasis and seborrhoiec keratoses point out.
Although MMP-26 has been detected in vitro in periph-
eral leukocytes and lymphocytes (Park et al, 2000; Nuttall
et al, 2003) as well as in fibroblasts and macrophages in
other tissues than skin (Bar-Or et al, 2003; Marchenko et al,
2004), our study, like several previous reports, confirms its
epithelial origin in vivo. Furthermore, MMP-26 has recently
been found also in epithelial corneal and conjunctival cells
in vivo (Marchenko et al, 2004). In tumor samples charac-
terized by dermal solar damage, MMP-26 was seen in
Figure 4
Matrix metalloproteinase (MMP)-26 expression disappears along with cancer dedifferentiation. (A) MMP-26 staining in a microinvasive
squamous cell cancer (SCC). (B) Serial section stained for elastin. (C) MMP-26 staining in a grade I SCC. (D) Serial section stained with laminin-5
(LN-5). (E) Higher magnification of MMP-26. (F) LN-5-positive cells in a grade II SCC. (G) Grade III SCC showing absence of MMP-26 from
dedifferentiated tumor cell islands. (H, I) Serial sections of a grade II SCC stained for MMP-26 and MMP-9. Arrows depict corresponding regions.
Scale bars: 125 mm (A–D, G); 50 mm (E, F); 25 mm (H, I).
Figure 5
Matrix metalloproteinase (MMP)-26 protein is expressed by cul-
tured keratinocyte (KC). (A) HaCaT cells cultured on type I collagen.
(B) Negative control with pre-immune serum. (C) Positive A-431
squamous cancer cells. (D) Primary KC grown on fibronectin. (E) KC
cultured in DMEM. Cells were cultured on LabTek chamber slides,
aminoethylcarbazole was used as chromogenic substrate and coun-
terstaining was performed with hematoxylin. Scale bars: 25 mm (A, B);
12.5 mm (C); 50 mm (D, E).
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fragmented or homogenized elastin. The closely related
enzymes, MMP-7 and MMP-12, are able to degrade elastin,
but this has not yet been examined in conjunction with
MMP-26.
In cutaneous wounds and well-differentiated cancers,
MMP-26 was found to co-localize with cytoplasmic LN-5.
MMP-2 and -14 process LN-5 g2 chain, revealing a cryptic
site inducing epithelial cell migration (Koshikawa et al,
2000). Several other MMP have recently been shown to be
capable of the same in vitro (Pirila¨ et al, 2003), but MMP-26
was inactive against LN-5 (Marchenko et al, 2001). Since
the physiologic substrates of MMP-26 include type IV col-
lagen and fibronectin (Urı´a and Lope´z-Otı´n, 2000), it may be
needed to degrade these substances during KC migration.
Our data suggest that MMP-26 may be regulated by LN-5,
which was not among the matrices tested in our experi-
ments using KC, HaCaT or A-431 cells.
MMP-26 resembles novel MMP, like MMP-19 and -28,
more than the older ones, as it was expressed already in
pre-malignant lesions and disappeared from most dediffer-
entiated SCC (Saarialho-Kere et al, 2002; Impola et al,
2003). This agrees with our previous results on oral SCC
(Impola et al, 2004) and with the data by Zhao et al (2004),
who found lower levels of MMP-26 in ductal carcinoma
in situ than in infiltrating ductal breast carcinoma, suggest-
ing that once the BM has been breached, cancer cells
become less dependent on the activity of MMP-26. Fur-
thermore, the tumor-to-normal tissue ratio of MMP-26 both
in kidney tissue and endometrium carcinoma is consider-
ably different from those of MMP classically associated with
malignancy and MMP-26 is detected in many carcinomas
as well as matching normal tissues (Isaka et al, 2003;
Marchenko et al, 2004).
P16 is a tumor suppressor gene promoting cell arrest in
the G1 stage and cell senescence (see Nakamura and Ni-
shioka, 2003), and its alterations have been described in
skin cancers, such as melanoma and head and neck SCC
(see Salama et al, 2003). Inactivation of p16 may be a cru-
cial molecular event leading to progression of actinic kera-
tosis to SCC (Mortier et al, 2002). P16 is not induced by
chronic hyperplasia but instead in cells that have pro-
gressed to the stage of incipient or initial invasion. Para-
doxically it is expressed also by migrating KC in vitro
(Natarajan et al, 2003) and these results show, for the first
time, that this is also true in vivo. P16 is absent in HaCaT
cells but upregulated in confluent KC (Chaturvedi et al,
1999). The observation that in stimulation experiments Ha-
CaT cells and 70%–80% confluent KC turned out negative
may thus suggest similar regulation for MMP-26 and p16.
MMP-26 has previously been shown to be regulated by
steroids during the endometrial cycle (Goffin et al, 2003;
Pilka et al, 2003). We tested in cultured KC the effects of
various cytokines and matrices, implicated to be important
during wound repair and cancer, on MMP-26 mRNA ex-
pression without clear-cut results. Neither did 12-phorbol-
13-myristate-acetate (PMA) upregulate MMP-26, unlike
found previously on HUVEC, MRC-5, and PC3 cells (Nut-
tall et al, 2003). It is possible that more than two cytokines at
the same time, hypoxia or certain integrin interactions are
needed for its induction, or that events we detect in vivo,
where cell–cell and cell–matrix interactions govern MMP
expression, cannot be recapitulated in simplistic cell culture
models.
The promoter of MMP-26 contains a consensus TATA
box and Tcf-4 and AP-1 elements. Although it has been
suggested that AP-1-mediated regulation of MMP-26 is like
to involve Ras (Marchenko et al, 2004), we did not find dif-
ferences in the levels of MMP-26 mRNA or protein in various
ras-transformed HaCaT clones. The Tcf-4 element is sub-
jected exclusively to regulation through the b-catenin/E-
cadherin pathway considered essential or exclusive for ep-
ithelial cell adherence (Marchenko et al, 2002a). This also
agrees with the presence of MMP-26 in anagen hair folli-
cles, since activation of this pathway is sufficient to initiate
the anagen phase (van Mater et al, 2003). But unlike in the
very recent study by Yamamoto et al (2004), we did not
detect correlation of MMP-26 protein and nuclear b-catenin
expression in our SCC (data not shown).
MMP-7 is structurally closely related to MMP-26 and
they both seem to be expressed by epithelial cells in vivo,
although they have distinct substrate specificities and tran-
scriptional regulation (Park et al, 2000). Unlike MMP-7,
MMP-26 was not detected in cutaneous sweat glands and
neither did they co-localize in SCC. This suggests that the
function of MMP-26 may differ from that of MMP-7, agree-
ing with data on differential regulation of these enzymes
Figure 6
Matrix metalloproteinase (MMP)-26 mRNA expression in cultured
keratinocytes, placenta, and testis. (A) MMP-26 mRNA expression is
low in unstimulated primary keratinocyte (KC) and HaCaT cells. Primary
keratinocytes were cultured and supplemented as described in Mate-
rials and Methods. Total RNA was extracted, reverse transcribed, and
analyzed by real-time quantitative RT-PCR (Applied Biosystems) using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as endogenous
control. Results are shown relative to mRNA levels from control primary
KC, assigned the value 1. (B) Expression of MMP-26 (upper lane) and
GAPDH (lower lane) in transformed (HaCaT) and primary KC by RT-
PCR. HaCaTcells and normal keratinocytes were cultured as described
above. Total RNA was reverse transcribed to cDNA and reverse tran-
scriptase PCR was performed.
MMP-26 IN SKIN BIOLOGY 853124 : 4 APRIL 2005
during endometrial cycle (Pilka et al, 2003). Even if MMP-26
and MMP-9 expressions did not co-localize in vivo, they
were detected in the same regions. Thus, we cannot ex-
clude that MMP-26 is a physiological activator of MMP-9
also in cutaneous disorders (Zhao et al, 2003).
In conclusion, our results demonstrate that whereas nor-
mal KC in vivo do not express the recently evolved MMP-
26, it is upregulated once the BM becomes disrupted in
various benign skin disorders, during initial stages of wound
repair and cancer invasion. It behaves unlike many classic
MMP that are rarely produced by normal tissues without
inflammatory or oncogenic stimuli: MMP-26 may thus have
a role in normal tissue turnover after injury or initiation of
cancer invasion. The expression pattern of MMP-26 in
highly differentiated SCC resembled that of the tumor sup-
pressor p16 and the disappearance of MMP-26 from the
invasive dedifferentiated SCC suggest that it is important in
early cutaneous tumorigenesis, whereas other members of
the MMP family drive the invasive phenomena. Thus, lack of
MMP-26 from SCC could be a marker of aggressive growth.
Materials and Methods
Chemicals and materials Cell culture media, cytokines, and
chemicals were from Sigma (St Louis, Missouri), Roche Molecular
Biochemicals (Indianapolis, Indiana), or Promega (Madison, Wis-
consin), fetal calf serum from Biowhittaker (Berkshire, UK), cell
culture plastic ware and Lab-Tek chamber slides from Nunc
(Naperville, Illinois), and thermostable polymerases from Clontech
(Palo Alto, California). KC growth medium (KGM) was from Clone-
tics (Cambrex Bio Science Walkersville, East Rutherford, New Jer-
sey), and reagents for real-time quantitative PCR from Applied
Biosystems (Warrington, UK). Cell culture vessels coated with col-
lagens I and IV, LN-1, and fibronectin were from BioCoat, BD Sci-
ences (Palo Alto, California).
Cell cultures, cytokines, and growth factors The immortalized
KC cell lines HaCaT, A5, II-4, and RT3 (Boukamp et al, 1990) and A-
431 cells (SCC line, ATCC) were cultured as previously described
(Saarialho-Kere et al, 2002; Ahokas et al, 2003). HaCaT cells and
primary KC were also cultured on four different matrices (collagens
I and IV, LN-1, and fibronectin). From matrices cells were lyzed and
RNA was extracted.
Human primary KC from adult skin obtained by reductive ma-
mmoplastic surgery from several patients were isolated, cultured,
and stimulated as described previously (Impola et al, 2003). KC
were maintained in KGM (Clonetics) in low Ca2þ (0.09 mM). One
hundred units of penicillin and 100 mg per mL streptomycin were
added to serve as antibiotic agents. Passages 1–4 were used in the
experiments. Cells were seeded 1:2–1:3 as they reached conflu-
ence. Primary KC, HaCaTclones, and A-431 cell were also cultured
on LabTek Chamber slides (Nunc, Naperville, Illinois) and immuno-
stained (Saarialho-Kere et al, 2002).
To study the regulation of MMP-26 expression, equal amounts
of HaCaT cells or primary KC were plated on tissue culture plates
and allowed to reach 70%–80% confluence. Then the cells were
depleted of supplements and serum overnight prior to stimulation
with PMA (10 ng per mL, Sigma), epidermal growth factor (10 ng
per mL, Sigma), IGF (10 ng per mL, Sigma), tumor necrosis factor-a
(10 ng per mL, Sigma), transforming growth factor-b1 (10 ng per
mL, Sigma), interleukin-1b (IL-1b, 5 U per mL, Roche Molecular
Biochemicals), IL-6 (1 ng per mL, Sigma), dexamethasone (Dxm,
105 M, Sigma), retinoic acid (RA, 106 M, Sigma), or high Ca2þ
(1.8 mM) concentration. Stimulation was allowed to proceed for
either 24 or 48 h after which the cells were lyzed and total RNA was
extracted using RNeasy Mini-kit (Qiagen, Chatsworth, California)
as instructed by the manufacturer. Cells given fresh serum-and-
supplement-free medium were used as controls. All treatments
were carried out in triplicate, and the results were confirmed in at
least three independent experiments on both cell types.
PCR primers and probes TaqMan PCR primers and probes
(Applied Biosystems) for human MMP-26 were designed using
Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi). The sequences of the primers for MMP-26 are: T-26-F
(50-ACGTTGGATGGTCAGCTTCAGACACTGGATATA-30) and T-26-
R (50-ACGTTGGATGGGTACATTATGGAGCTCTGATTC-30) (Applied
Biosystems). The fluorogenic probe (50-AGATTGGGCATTCTTTGG-
GC-30) contained a reporter dye (FAM) (Applied Biosystems,
Warrington, UK) covalently attached at the 50-end and a quenc-
her dye (TAMRA) (Applied Biosystems, Warrington, UK) covalently
attached at the 30-end. Human glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) labeled with VIC reporter dye (Applied
Biosystems, Warrington, UK) (pre-developed TaqMan assay rea-
gents for endogenous control human GAPDH, Applied Biosystems)
was used as an endogenous control in quantitative real-time PCR
(TaqMan). MMP-10, which can be induced in cultured KC by sev-
eral agents employed in this study, was used as a positive control
as described previously (Rechardt et al, 2000).
PCR of expression for MMP-26 PCR analyses were performed
using the cDNA reverse transcribed for real-time PCR analyses.
Human embryonic kidney cells (293) (de Coignac et al, 2000) as
well as placenta poly(A) RNA (Ambion, Austin, Texas) and human
testis total RNA (Clontech) were used as positive controls for
MMP-26 expression. PCR assays were performed in 25 mL vol-
umes using 3 mL of cDNA, 200 nM of each primer (T-26-F, T-26-R,
GAPDH forward and GAPDH reverse) (Zhao et al, 2003), 1  re-
action buffer for Hot Star Taq polymerase, 400 mM of each nuc-
leotide, and 1 U of Hot Star Taq polymerase (Qiagen). PCR was
carried out as follows: 951C for 15 min, 40 cycles of 951C for 20 s,
561C for 30 s, and 721C for 60 s, followed by 721C for 3 min. MMP-
26 and GAPDH reactions were done in separate tubes. The reac-
tion products were run in a 2% agarose gel, stained with 5 ng per
mL ethidium bromide, and visualized under ultraviolet light. The
identity of the positive bands was confirmed by sequencing.
Quantitative real-time PCR (TaqMan RT-PCR) Half a microgram
of total cellular RNA from cultured cells was reverse transcribed to
complementary DNA (cDNA) with SuperScript III first-strand syn-
thesis system (Invitrogen, Carlsbad, California) with oligo dT and
used as a template for TaqMan real-time quantitative PCR. Reac-
tions were performed with the ABI PRISM 7700 Sequence De-
tection System (Applied Biosystems) as described previously (Sa-
arialho-Kere et al, 2002). PCR amplifications were performed in 25
mL volumes, MMP-26 and GADPH in separate reactions. The mix
contained 200 nM primers and 100 nM probe for MMP-26 or 1.25
mL of the 20  ready-to-use primer and probe mix for GAPDH, 9
mL of the undiluted cDNA, and 1  TaqMan Universal Master Mix.
The PCR was started with 2 min at 501C and an initial 10 min
denaturation at 941C, followed by a total of 40 cycles of 15 s de-
naturation at 941C, and 1 min of annealing and elongation at 601C.
Tissues The use of paraffin-embedded, formalin-fixed samples of
human skin cancers and wounds was approved by the medical
ethical committee of the Department of Dermatology, Helsinki,
University Central Hospital, Finland. Specimens from adult patients
were obtained from the Department of Dermatopathology, Skin,
and Allergy Hospital, University of Helsinki, Finland in compliance
with the Declaration of Helsinki guidelines. Informed consent was
obtained from individual subjects undergoing reductive ma-
mmoplasty for assays employing human primary KC. Tissue sam-
ples included normally healing timed wounds (1–9 d; n¼ 10)
(Vaalamo et al, 1996), chronic wounds (n¼ 10), psoriasis (n¼ 3),
lichen planus (n¼ 3), chronic eczema (n¼ 3), alopecia (n¼ 5), solar
elastosis (n¼ 3), keratoacanthomas (n¼ 6), seborrhoeic keratoses
(n¼ 3), actinic keratoses (n¼ 5), Bowen’s disease (n¼ 2), BCC
(n¼ 6), SCC (n¼ 25; microinvasive 3, grade I 7, grade II 7, grade III
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8), developing skin from gestational week 20 (n¼ 1) and normal
skin (n¼ 3). Diagnoses were confirmed by an experienced der-
matopathologist (L. J.).
Immunohistochemistry Immunostaining was performed using
the avidin–biotin–peroxidase complex technique (StreptABComplex/
HRP Duet kit, Dako A/S, Glostrup, Denmark or Vectastain Elite
Rabbit kit, Vector Laboratories, Burlingame, California). Di-
aminobenzidine or aminoethylcarbazole (for Ki-67 and cells cul-
tured on chamber slides) were used as chromogenic substrates
and Mayer hematoxylin as counterstain. For negative controls we
used pre-immune sera or normal rabbit/mouse immunoglobulin.
Pre-tested dilutions of monoclonal antibodies against MMP-9
(1:50, Research Diagnostics, Flanders, New Jersey) (Impola et al,
2004), MMP-7 (1:80, Oncogene Research Products, Cambridge,
Massachusetts) (Impola et al, 2004), E-cadherin (1:200-1:400,
Zymed Laboratories, South San Francisco, California), b-catenin
(1:1000, C19220, Transduction Laboratories, Lexington, Kentucky),
and p16INK4 (1:350, BD Pharmingen, San Diego, California) were
used. Immunostaining for MMP-26 using two different reagents
(1:150; Isaka et al, 2003 or 1:400; Bister et al, 2004), the g-chain of
LN-5 (1:800, a gift from Prof. Karl Tryggvason, Karolinska Institute,
Stockholm, Sweden) (Pyke et al, 1994), and Ki-67 (1:200, Dako
A/S) was performed using polyclonal antibodies. Staining for re-
vealing elastic fibers was performed on serial sections using
Weigert’s elastin stain (Weigert’s Resorcin–Fuchsin).
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